[Market Focus] Anticipation of Additional Technology Transfers... NIBEC Surges Over 15%

Shares of the biotech company NIBEC are on the rise amid expectations that additional technology transfer deals will drive the stock price upward.

As of 11:05 a.m. on September 26, NIBEC was trading at 31,400 won, up 4,250 won (15.65%) from the previous trading day.

Previously, at the end of May, NIBEC licensed out its fibrosis treatment NP-201 to a U.S.-based pharmaceutical and biotech company for an upfront payment of 8 million dollars and milestone payments of up to 427 million dollars. This treatment has completed Phase 1 clinical trials in Australia and is preparing to enter Phase 2 trials in the United States. The partner company is NewCo, which specializes in lung diseases.

On this day, Huh Hyemin, a researcher at Kiwoom Securities, commented on NIBEC, saying, "The company still has catalysts such as the disclosure of its partner, a conference presentation in the fourth quarter, and additional technology transfer deals." She added, "Each time these achievements are confirmed, a stepwise upward trend is expected."

Researcher Huh noted, "What is unique about this technology transfer deal is that the contract was structured not by region, but by therapeutic area." She explained, "Outside of lung diseases, NIBEC retains the opportunity for additional technology transfers in the fields of obesity, oncology, and neurological disorders, as it can independently develop and commercialize in these areas."

She also added, "A new mechanism pulmonary arterial hypertension (PAH) treatment based on artificial intelligence (AI)-powered multi-target peptides is currently in preclinical development." She continued, "This is the partner company's area of expertise, and since they hold the right of first negotiation, additional technology transfer deals are likely."

This content was produced with the assistance of AI translation services.